Loading chart...
MRKMRK
$146.63Down 0.35 percent, −$0.52
As of Sep 18 at 4:00 PM ET
Key Stats
Market Cap$362.353B
Volume (24h)6,533,327
Day's Range$145.77-$147.76
52-Week Range$77.58-$156.92
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).
- Website
- merck.com
- Industry
- PHARMACEUTICAL PREPARATIONS
- Full-time Employees
- 75,000
- Headquarters
- RAHWAY
- IPO Date
- Apr 20, 1949
| 24 hours | 5 days | 1 month | YTD | 1 year | All time |
|---|---|---|---|---|---|
Down 0.35 percent | Up 1.23 percent | Down 3.66 percent | Up 38.25 percent | Up 79.89 percent | — |
Latest MRK News
Neutral
(opens in a new tab)
Can AstraZeneca's Broad Pipeline Offset Recent Setbacks?
Positive(opens in a new tab)
Is Cancer the Turnaround Moderna Has Been Looking for Post-COVID?
Neutral(opens in a new tab)
Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study
Positive
(opens in a new tab)
Immunotherapy Drugs Market 2026: Precision Medicine, Next-Generation Biologics and Expanding Cancer Indications Fuel Growth Opportunities
Neutral(opens in a new tab)
Parexel to Lead Sessions at DPHARM 2026 on AI, Talent and the Future of Clinical Operations
Positive(opens in a new tab)
